Lilly’s Omvoh shows sustained 4-year efficacy in ulcerative colitis
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
IMCD engaged with manufacturers, formulators, and brand leaders, offering valuable insights into evolving consumer trends
States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Marks first international filing for Evofem’s single-dose oral treatment
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Hyperion results presented at ERS 2025 and simultaneously published in the New England Journal of Medicine
The Hub & Spoke model is designed to extend advanced medical care to a wider community
Subscribe To Our Newsletter & Stay Updated